Comparison of cellular and biochemical markers of airway inflammation in patients with mild-to-moderate asthmaand chronic obstructive pulmonary disease: AN induced sputum and bronchoalveolar lavage fluid study

Journal of Physiology and Pharmacology

Volumn 59, Issue SUPPL. 6, 2008, Pages 271-283

  Gorska, K ^a   Krenke, R ^a   Domagala Kulawik, J ^a   Korczynski, P ^a   Nejman Gryz, P ^a   Kosciuch, J ^a   Hildebrand, K ^a   Chazan, R ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Asthma; BALF; COPD; IL 8; Induced sputum; MPO

Indexed keywords

BIOCHEMICAL MARKER; CELL MARKER; INTERLEUKIN 8; MYELOPEROXIDASE; BIOLOGICAL MARKER; PEROXIDASE;

ADULT; AIRWAY INFLAMMATION; ARTICLE; ASTHMA; BRONCHOSCOPY; CELL COMPOSITION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; EOSINOPHIL COUNT; FEMALE; HUMAN; INTERMETHOD COMPARISON; LEUKOCYTE DIFFERENTIAL COUNT; LUNG LAVAGE; MACROPHAGE; MALE; MEDIATOR; RESPIRATORY TRACT INFLAMMATION; SPUTUM; SPUTUM ANALYSIS; AGED; CYTOLOGY; INFLAMMATION; LUNG FUNCTION TEST; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; ASTHMA; BIOLOGICAL MARKERS; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHOSCOPY; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-8; MALE; MIDDLE AGED; PEROXIDASE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; SPUTUM;

EID: 64549126914     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Fabbri LM, Romagnoli M, Corbetta L et al. Differences in Airway Inflammation in Patients with Fixed Airflow Obstruction Due to Asthma or Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2003; 167: 418-424.
2. Silkoff PE, Trudeau JB, Gibbs R, Wenzel S. The relationship of induced-sputum inflammatory cells to BAL and biopsy. Chest 2003; 123 Suppl 3: 371s-372s.
3. Rutgers SR, Timens W, Kaufmann HF et al. Comparison of induced sputum with bronchial wash, bronchoalveolar lavage and bronchial biopsies in COPD. Eur Respir J 2000; 15: 109-115.
4. Beeh KM, Kornmann O, Buhl R et al. Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4. Chest 2003; 123: 1240-1247.
5. Larsen CG, Anderson AO, Appella E et al. The neutrophil-activating protein (NAP-1) is also chemotactic for T lymphocytes. Science 1989; 243: 1464-1466.
6. Standardized lung function testing. Official statement of the European Respiratory Society. Eur Respir J Suppl 1993; 16: 1-100.
7. GINA Global Initiative for Asthma: Global strategy for asthma management and prevention. NHLBI/WHO 2002.
8. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO workshop report. 2001.
9. Djukanovic R, Sterk PJ, Fahy JV, Hargreave FE. Standardised methodology of sputum induction and processing. Eur Respir J 2002; 20, Suppl 37.
10. Gorska K, Krenke R, Kosciuch J et al. The relationship between markers of airway inflammation and thickness of the basement membrane in patients with asthma. Pneumonol Alergol Pol 2007; 75: 363-369.
11. Domagala-Kulawik J, Maskey-Warzechowska M, Hermanowicz J, Chazan R. Expression of macrophage surface markers in induced sputum of patients with chronic obstructive pulmonary disease. J Physiol Pharmacol 2006; 57 Suppl 4: 75-84.
12. Belda J, Leigh R, Parameswaran K et al. Induced sputum cell counts in healthy adults. Am J Respir Crit Care Med 2000; 161: 475-478.
13. Krenke R, Przybylowski T, Hildebrand K et al. The effect of fiberoptic bronchoscopy on exhaled nitric oxide. J Physiol Pharmacol 2006; 57 Suppl 4: 183-190.
14. Safianowska A, Krenke R, Grubek-Jaworska H et al. Oznaczanie enzymu przeksztalcaja̧cego angiotensynȩ (ACE) w surowicy i w plynie z phikania oskrzelowo-pecherzykowego (BALF) u chorych na sarkoidozȩ. Pneumonol Alergol Pol 1994; 62 Suppl. 4: 39-45.
15. 1. Am J Respir Crit Care Med 1997; 155: 852-857.
16. Keatings VM, Collins PD, Scott DM et al. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with COPD or asthma. Am J Respir Crit Care Med 1996; 153: 530-534.
17. Currie GP, Syme-Grant NJ, McFarlane LC et al. Effects of low dose fluticasone/salmeterol combination on surrogate inflammatory markers in moderate persistent asthma. Allergy 2003;58: 602-607.
18. Iiboshi H, Ashitani J, Katoh S et al. Long-term treatment with theophylline reduces neutrophils, interleukin-8 and tumor necrosis factor-alpha in the sputum of patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2007; 20: 46-51.
19. Louis R, Lau LC, Bron AO et al. The relationship between airways inflammation and asthma severity. Am J Respir Crit Care Med 2000; 161: 9-16.
20. Di Stefano A, Capelli A, Lusuardi M et al. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med 1998; 158: 1277-1285.
21. Gibson PG, Simpson JL, Saltos N. Heterogeneity of airway inflammation in persistent asthma: evidence of neutrophilic inflammation and increased sputum interleukin-8. Chest 2001; 119: 1329-1336.
22. Paggiaro P, Bacci E, Paoletti P et al. Bronchoalveolar lavage and morphology of the airways after cessation of exposure in asthmatic subjects sensitized to toluene diisocyanate. Chest 1990;98: 536-542.
23. Fahy JV, Kim KW, Liu J et al. Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation. J Allergy Clin Immunol 1995; 95: 843-852.
24. Wenzel SE, Schwartz LB, Langmack EL et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999; 160: 1001-1008.
25. Hoser G, Domagala-Kulawik J, Droszcz P et al. Lymphocyte subsets differences in smokers and nonsmokers with primary lung cancer: a flow cytometry analysis of bronchoalveolar lavage fluid cells. Med Sci Monit 2003; 9: BR310-BR315.
26. Rutgers SR, Postma DS, ten Hacken NH et al. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax 2000; 55: 12-18.
27. Amin K, Ludviksdottir D, Janson C et al. Inflammation and structural changes in the airways of patients with atopic and nonatopic asthma. BHR Group. Am J Respir Crit Care Med 2000, 162, 2295-2301.
28. Lacoste JY, Bousquet J, Chanez P et al. Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis and chronic obstructive pulmonary disease. J Allergy Clin Immunol 1993; 92:537-548.
29. Bousquet J, Chanez P, Lacoste J et al. Indirect evidence of bronchial inflammation assessed by titration of inflammatory mediators in BAL fluid of patients with asthma. J Allergy Clin Immunol 1991; 88: 649-660.
30. Yamamoto C, Yoneda T, Yoshikawa M et al. Airway inflammation in COPD assessed by sputum levels of interleukin-8. Chest 1997; 112: 505-510.
31. Nocker RE, Schoonbrood DF, Van de Graaf EA et al. Interleukin-8 in airway inflammation in patients with asthma and chronic obstructive pulmonary disease. Int Arch Allergy Immunol 1996; 109: 183-191.
32. Linden M, Rasmussen JB, Piitulainen E et al. Airway inflammation in smokers with nonobstructive and obstructive chronic bronchitis. Am Rev Respir Dis 1993; 148: 1226-1232.